-

Biogennix Launches Agilon Surgical Matrix

Osteobiologics Leader Enters Wound Care Space with Cutting Edge Solution

IRVINE, Calif.--(BUSINESS WIRE)--Biogennix, an osteobiologics company specializing in innovative healing solutions for surgical procedures, has announced the launch of its new Agilon Surgical Matrix wound care product.

Agilon Surgical Matrix is a wound care solution derived from 100% bovine Type 1 collagen. Upon contact with a new or open wound, whether surgically or naturally occurring, Agilon Surgical Matrix transforms into a gel, enveloping the entire wound area. This coverage maintains a low pH wound environment that aids in the formation of tissue and epithelialization, which is conducive to successful wound healing.

Backed by in vitro performance data, Agilon Surgical Matrix demonstrates wide-ranging antimicrobial properties, offering added protection against infections. The product’s versatility extends to various surgical applications, serving as an alternative to close-suction drains, blood vessel ligation, or surgical site immobilization in preventing postoperative seromas.

With its sterile, single-use packaging, Agilon Surgical Matrix provides a safe and effective option for healthcare professionals and patients.

“Based on the enthusiastic feedback we’ve received from surgeons, we anticipate Agilon Surgical Matrix to be a significant addition to our product offering that will open the doors to a wide variety of indications,” said Greg Yocum, Biogennix’s VP of Business Development. “Because Agilon Surgical Matrix is purified low pH, bovine Type 1 collagen, it represents a significant advancement in surgical and post-operative care management, offering a myriad of benefits – including antibacterial properties – which enhance patient outcomes and facilitate healing. This product also opens the door for Biogennix to participate in the wound care market.”

Agilon Surgical Matrix can be used in the management of partial and full thickness wounds, pressure (stage I – IV) and venous ulcers, ulcers caused by mixed vascular etiologies, venous stasis and diabetic ulcers, first and second degree burns, cuts, abrasions, and surgical wounds.

Surgical areas include orthopedic, podiatry, cardiovascular, abdominal, neurologic, plastic/breast reconstruction, general, OB/GYN, trauma, vascular, burns, and ulcers.

About Biogennix:

Biogennix is a pioneering osteobiologics company based in Irvine, California, committed to developing, manufacturing, and distributing advanced products for surgical procedures. Its focus on innovation, quality, and customer satisfaction continues to set it apart as a leader in the medical device industry.

“Agilon” is a registered trademark of Biogennix.

Contacts

Paul Williams
(310) 569-0023
paul@medialinecommunications.com

More News From Biogennix

Biogennix Announces Publication of a Scientific Study on Its Advanced Bone Graft Technology

IRVINE, Calif.--(BUSINESS WIRE)--Biogennix, an osteobiologics company specializing in products for bone graft procedures, has announced the publication of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material. TrelCor is an innovative dual-phase bone graft featuring a nanocrystalline hydroxycarbanoapatite (HCA) surface, specially engineered for bone formation. The study, titled “Characterization of an Advanced Bone Graft Material with a Nanoc...

Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable and Morpheus Moldable Products

IRVINE, Calif.--(BUSINESS WIRE)--Irvine-based Biogennix, LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products. The new clearance allows the products to be used in the intervertebral disc space as an autograft extender, with an FDA-cleared intervertebral body fusion device...

Biogennix Launches OsteoSPAN Fiber Matrix

IRVINE, Calif.--(BUSINESS WIRE)--Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced the launch of its new OsteoSPAN Fiber Matrix. Consisting of 100% demineralized cortical fibers, OsteoSPAN Fiber Matrix has been engineered for optimized handling, while providing verified osteoinductive potential and an osteoconductive scaffold that supports cellular bone formation and sti...
Back to Newsroom